Skip to main content
. 2017 Mar;47:64–75. doi: 10.1016/j.exphem.2016.11.003

Figure 3.

Figure 3

Treatment with the DOT1L inhibitor EPZ5676 and loss of H3K79me2/3 causes reduced BCL-2 and MCL-1 transcription, but has no effect on BIM. (A) BCL-2 family genes ranked by levels of H3K79me2 with MCL-1, BCL-2, BID, and BIM displaying the top four highest levels of H3K79me2. Read count represents number of H3K79me2 reads over the entire gene, normalized to the length of the gene (RPK). (B) Gene transcription as measured by nascent RNA-seq and presented as FPKM values in control-treated (black bars) versus 2μM EPZ5676-treated (gray bars) SEM cells. Results are averages of three biological replicates. ***p (FDR) < 0.001. (C) The same data as in (B) normalized to the control samples to illustrate the extent of the gene transcription change. (D–G) RT-PCR of MCL-1, BCL-2, and BCL-XL in SEM cells treated with different dosages of the DOT1L inhibitor EPZ5676. Average of six independent experiments except (G), which was three independent experiments. *p < 0.05 using the Mann–Whitney U test. (H) Sample Western blots of one set of samples from (B) for the proteins/marks indicated. GAPDH and H4 are shown as loading controls.